Summary
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
History
Karyopharm Therapeutics was founded in 2008 by Dr. Sharon Shacham, Professor at Hadassah-Hebrew University Medical School and Philipp Goldsmith, a former investment banker at Goldman Sachs and OrbiMed. Karyopharm is pioneering the discovery and development of novel, first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.
Mission
We seek to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture that will accelerate first-in-class small molecule modulators of nuclear transport into effective therapeutics for life-threatening conditions.
At Karyopharm, we support a culture of innovation, courage, urgency, resiliency and energy with our employees and collaborators. Integrity and respect are core to our success.
Vision
Karyopharm Therapeutics Inc. is an innovation-driven pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases.
Key Team
Mr. Cameron Peters (VP of Fin., Assistant Treasurer & Principal Accounting Officer)
Mr. Ran Frenkel R.Ph., RPh (Global Head of Clinical Operations)
Dr. Mansoor Raza Mirza M.D. (Clinical Consultant, Member of Scientific Advisory Board & Independent Director)
Mr. James Accumanno J.D. (Chief Compliance Officer)
Mr. Pierre S. Sayad M.S., Ph.D. (VP of Global Medical & Scientific Affairs)
Ms. Elhan Webb C.F.A. (Sr. VP of Investor Relations)
Mr. Michael J. Mano J.D. (Sr. VP, Gen. Counsel & Sec.)
Recognition and Awards
Karyopharm Therapeutics won 1 award in 2022 and 4 awards in 2021. In 2022, Karyopharm Therapeutics won for Best Company Compensation. In 2021, Karyopharm Therapeutics won for Best Company Culture 2021, Best Company Compensation, Best Leadership Teams 2021 and Best Places to Work in Boston 2021. Based on 2,628 ratings and 90 participants, employees at Karyopharm Therapeutics are very satisfied with their work experience. The overall culture score, 79/100 or A-, incorporates employee ratings based on their feedback on the Team, Manager, Meetings and more.
References
United States 